297 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
22 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
23 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
24 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
25 Recruiting Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Conditions: Neoplasms,;   Breast Neoplasms,;   Kidney Neoplasms,;   Pancreatic Neuroendocine Neoplasms
Interventions: Drug: alpelisib;   Drug: everolimus;   Drug: exemestane
26 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
27 Recruiting Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Everolimus;   Drug: TRC105
28 Recruiting ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: Everolimus
29 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
30 Recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
31 Recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Adenocarcinoma;   Pancreatic Neoplasms
Interventions: Drug: X-82;   Drug: Everolimus;   Procedure: Blood draws for pharmacokinetic testing
32 Recruiting Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Conditions: Brain Tumor, Recurrent;   Glioblastoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Mixed Glioma
Interventions: Procedure: Cytoreductive surgery;   Drug: Perifosine;   Drug: Temsirolimus
33 Not yet recruiting Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Goserelin;   Drug: Letrozole
34 Recruiting DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Conditions: HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer;   HER2-negative Circulating Tumor Cells;   Postmenopausal Female Patients
Interventions: Drug: Everolimus;   Drug: Eribulin
35 Recruiting A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Conditions: Solid Tumors;   Lung Cancer
Interventions: Drug: BKM120;   Drug: Everolimus
36 Recruiting Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Condition: Cancer
Interventions: Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
37 Recruiting Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Condition: Breast Cancer
Interventions: Drug: Ribociclib;   Drug: Everolimus;   Drug: Exemestane
38 Recruiting A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
39 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo
40 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years